MediGene
Official site for Medigene. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies..
Enterprise value
($10m)
Share price
€0.13 MDG1.DE
Company register number
HRB 115761 (München)
Recent deals
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Post IPO Equity | |
| Total Funding | 000k | ||
Rho Canada Ventures(exited)
Oxford University Innovation(exited)
BioNTech(exited)
Techno Venture Management(exited)
Michael Nettersheim(exited)
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 87 % | (1 %) | 40 % | (18 %) | 20 % | 199 % | (81 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (158 %) | (215 %) | (161 %) | (246 %) | (62 %) | 42 % | (242 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (177 %) | (280 %) | (188 %) | (330 %) | (95 %) | (27 %) | (268 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 181 % | 208 % | 213 % | 254 % | 122 % | 91 % | 191 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by MediGene
Edit
ACQUISITION by Eurofins May 2001